108 related articles for article (PubMed ID: 10760375)
21. Dose-dependent effects of Delta9-tetrahydrocannabinol on rates of local cerebral glucose utilization in rat.
Freedland CS; Whitlow CT; Miller MD; Porrino LJ
Synapse; 2002 Aug; 45(2):134-42. PubMed ID: 12112406
[TBL] [Abstract][Full Text] [Related]
22. Effects of delta9-THC on VIP-induced prolactin secretion in anterior pituitary cultures: evidence for the presence of functional cannabinoid CB1 receptors in pituitary cells.
Rodríguez de Fonseca F; Wenger T; Navarro M; Murphy LL
Brain Res; 1999 Sep; 841(1-2):114-22. PubMed ID: 10546994
[TBL] [Abstract][Full Text] [Related]
23. Effects of chronic administration of delta 9-tetrahydrocannabinol on the cardiovascular system, and pressor and behavioral responses to brain stimulation in freely moving rats.
Kawasaki H; Watanabe S; Ueki S
Eur J Pharmacol; 1980 Jul; 65(1):63-9. PubMed ID: 6249621
[TBL] [Abstract][Full Text] [Related]
24. Changes in rat brain cannabinoid binding sites after acute or chronic exposure to their endogenous agonist, anandamide, or to delta 9-tetrahydrocannabinol.
Romero J; García L; Fernández-Ruiz JJ; Cebeira M; Ramos JA
Pharmacol Biochem Behav; 1995 Aug; 51(4):731-7. PubMed ID: 7675852
[TBL] [Abstract][Full Text] [Related]
25. Lack of hippocampal CB1 receptor desensitization by Δ(9)-tetrahydrocannabinol in aged mice and by low doses of JZL 184.
Feliszek M; Bindila L; Lutz B; Zimmer A; Bilkei-Gorzo A; Schlicker E
Naunyn Schmiedebergs Arch Pharmacol; 2016 Jun; 389(6):603-12. PubMed ID: 26984820
[TBL] [Abstract][Full Text] [Related]
26. Changes in rat brain energetic metabolism after exposure to anandamide or Delta(9)-tetrahydrocannabinol.
Costa B; Colleoni M
Eur J Pharmacol; 2000 Apr; 395(1):1-7. PubMed ID: 10781666
[TBL] [Abstract][Full Text] [Related]
27. Regulation of delta opioid receptors by delta9-tetrahydrocannabinol in NG108-15 hybrid cells.
Di Toro R; Campana G; Sciarretta V; Murari G; Spampinato S
Life Sci; 1998; 63(14):PL197-204. PubMed ID: 9771917
[TBL] [Abstract][Full Text] [Related]
28. Molecular mechanisms involved in the asymmetric interaction between cannabinoid and opioid systems.
Viganò D; Rubino T; Vaccani A; Bianchessi S; Marmorato P; Castiglioni C; Parolaro D
Psychopharmacology (Berl); 2005 Nov; 182(4):527-36. PubMed ID: 16079992
[TBL] [Abstract][Full Text] [Related]
29. Regulation of delta-opioid receptor mRNA levels by receptor-mediated and direct activation of the adenylyl cyclase-protein kinase A pathway.
Buzas B; Rosenberger J; Cox BM
J Neurochem; 1997 Feb; 68(2):610-5. PubMed ID: 9003047
[TBL] [Abstract][Full Text] [Related]
30. Increment of in vivo binding of [3H]SCH 23390, a dopamine D1 receptor ligand, induced by cyclic AMP-dependent protein kinase in rat brain.
Abe K; Hosoi R; Momosaki S; Kobayashi K; Ibii N; Inoue O
Brain Res; 2002 Oct; 952(2):211-7. PubMed ID: 12376181
[TBL] [Abstract][Full Text] [Related]
31. Biphasic effects of Δ9-tetrahydrocannabinol on brain stimulation reward and motor activity.
Katsidoni V; Kastellakis A; Panagis G
Int J Neuropsychopharmacol; 2013 Nov; 16(10):2273-84. PubMed ID: 23830148
[TBL] [Abstract][Full Text] [Related]
32. cAMP/PKA-CREB-BDNF signaling pathway in hippocampus mediates cyclooxygenase 2-induced learning/memory deficits of rats subjected to chronic unpredictable mild stress.
Luo Y; Kuang S; Li H; Ran D; Yang J
Oncotarget; 2017 May; 8(22):35558-35572. PubMed ID: 28415673
[TBL] [Abstract][Full Text] [Related]
33. Stereochemical effects of 11-OH-delta 8-tetrahydrocannabinol-dimethylheptyl to inhibit adenylate cyclase and bind to the cannabinoid receptor.
Howlett AC; Champion TM; Wilken GH; Mechoulam R
Neuropharmacology; 1990 Feb; 29(2):161-5. PubMed ID: 2158635
[TBL] [Abstract][Full Text] [Related]
34. Oxidative stress and cannabinoid receptor expression in type-2 diabetic rat pancreas following treatment with Δ⁹-THC.
Coskun ZM; Bolkent S
Cell Biochem Funct; 2014 Oct; 32(7):612-9. PubMed ID: 25187240
[TBL] [Abstract][Full Text] [Related]
35. Effects of chronic Delta(9)-tetrahydrocannabinol treatment on hippocampal extracellular acetylcholine concentration and alternation performance in the T-maze.
Nava F; Carta G; Colombo G; Gessa GL
Neuropharmacology; 2001 Sep; 41(3):392-9. PubMed ID: 11522331
[TBL] [Abstract][Full Text] [Related]
36. [Changes of AC/cAMP system and phosphorylation regulation of adenylate cyclase activity in brain regions from morphine-dependent mice].
Fang F; Wang Q; Cao Q; Liu J
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2000 Feb; 22(1):14-9. PubMed ID: 12903486
[TBL] [Abstract][Full Text] [Related]
37. Modulation of rat brain cannabinoid receptors after chronic morphine treatment.
Rubino T; Tizzoni L; Viganò D; Massi P; Parolaro D
Neuroreport; 1997 Oct; 8(15):3219-23. PubMed ID: 9351646
[TBL] [Abstract][Full Text] [Related]
38. Time-course of the effects of chronic delta 9-tetrahydrocannabinol on behaviour, body temperature, brain amines and withdrawal-like behaviour in the rat.
Taylor DA; Fennessy MR
J Pharm Pharmacol; 1982 Apr; 34(4):240-5. PubMed ID: 6124598
[TBL] [Abstract][Full Text] [Related]
39. Large-scale analysis of gene expression changes during acute and chronic exposure to [Delta]9-THC in rats.
Kittler JT; Grigorenko EV; Clayton C; Zhuang SY; Bundey SC; Trower MM; Wallace D; Hampson R; Deadwyler S
Physiol Genomics; 2000 Sep; 3(3):175-85. PubMed ID: 11015613
[TBL] [Abstract][Full Text] [Related]
40. Involvement of sphingomyelin hydrolysis and the mitogen-activated protein kinase cascade in the Delta9-tetrahydrocannabinol-induced stimulation of glucose metabolism in primary astrocytes.
Sánchez C; Galve-Roperh I; Rueda D; Guzmán M
Mol Pharmacol; 1998 Nov; 54(5):834-43. PubMed ID: 9804618
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
